
|Videos|March 27, 2015
Lymph Node Dissection in Bladder Cancer
Advertisement
Episodes in this series

For High-Definition, Click
The number of lymph nodes removed from individuals with muscle-invasive bladder cancer is being used as a surrogate measure for the quality of the dissection, says Dean F. Bajorin, MD. There are studies looking at defining a dissection up to the bifurcation of the iliacs versus up to the bifurcation of the aorta, and whether greater or extended lymph node dissection makes a difference.
It is important to standardize the way the procedure is performed to maintain consistency from institution to institution. Ongoing clinical trials are assessing how a dissection should be defined, including the definitions of standard dissection and extended dissection.
Advertisement
Related to this article

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5











